title: Gastric carcinoma.
abstract: Although gastric cancer is still a worldwide major public health concern, it remains relatively uncommon in the Western countries. Despite improvement in surgical morbidity and mortality, as well as significant advancement of chemotherapy and radiotherapy options, the survival for gastric cancer has not significantly improved over the past decades. In the United States, standard of care for localized resectable gastric cancer is with adjuvant chemoradiotherapy. In this article, we summarize salient randomized and phase II and III clinical trials representing current treatment for gastric cancer.
authors.affiliation: University of Texas MD Anderson Cancer Center, GI Medical Oncology Department, 1515 Holcombe Boulevard, Mailbox 426, Houston, TX 77030, USA. aphan@mdanderson.org
authors.forename: Alexandria T
authors.initials: AT
authors.lastname: Phan
authors.forename: Jaffer A
authors.initials: JA
authors.lastname: Ajani
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D005743:Gastrectomy; D014943:Global Health; D006801:Humans; D009367:Neoplasm Staging; D012307:Risk Factors; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D016019:Survival Analysis; D014481:United States / Q000453:epidemiology